.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its own best biopharma choice for 2025 and also ranked an additional nine labels in the space as over weight. The expenditure banking company claimed in a keep in mind that it continues to feel “diabesity is actually readied to become.